secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2022-03-17T23:59:59+00:00
Accession:  0001193125-22-077895
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic Q4 2021 net loss $15.1M; cash $136.6M; PKU Phase 3 on track for H2 2022
--------------------------------------------------------------------------------

- Q4 2021 net loss $15.1M ($0.21/share) vs $14.6M ($0.39/share) in Q4 2020; FY 2021 net loss $60.6M ($1.09/share).
- Cash, equivalents & marketable securities $136.6M at Dec 31, 2021; projected runway into 2024.
- PKU program: Phase 2 SynPheny-1 data expected H1 2022; Phase 3 trial initiation planned H2 2022.
- Appointed Michael Jensen as CFO in March 2022; he was formerly CFO of Intrinsic Therapeutics.
- HCU candidate SYNB1353 IND submission and Phase 1 healthy volunteer data expected H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000119312522077895/0001193125-22-077895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000119312522077895/d284910d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-077895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer